Two psychosocial treatments and three drug treatments for cocaine dependence will be compared in a random assignment study, over a four week treatment period. The psychosocial treatments compared will be a one month 15 hour a week day hospital or a six hours, three times a week outpatient program. The drug conditions will be 300 mg daily of amantadine hydrochloride, 300 mg. daily of placebo, or a nonmedication condition. The drug trial will be conducted double blind. Two hundred and forty (240) cocaine dependent men will be studied, 40 in each of the six treatment conditions. Subjects will be followed over a two year period. One half of the subjects will be followed every two months during the first year and every three months in the second year; while the remaining subjects will be followed every six months for two years. A baseline assessment battery will measure psychopathology, risk for AIDS behavior, cocaine and alcohol use, substance abuse related problems, social support, abstinence commitment, moods, and self efficacy. Some of these measures will also be re-evaluated during some of the followup evaluations. Costs during the two year study period will also be ascertained. In study years 3, 4, and 5 promising drugs will be studied in double blind, placebo controlled fashion. This study will provide critical information concerning the efficacy and cost effectiveness of two forms of psychosocial treatment for cocaine dependence. It will also yield important information about the effectiveness of amantadine hydrochloride under two levels of psychosocial treatment. Subsequent drug trials will benefit from the study findings by being able to use the minimal psychosocial treatment found to be effective in the initial study. The study will provide important detailed information about the course of response to treatment for cocaine dependence over a two year followup period. Predictors of favorable treatment response will also be ascertained.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005186-10
Application #
5209638
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1996
Total Cost
Indirect Cost
Jaremko, Kellie M; Thompson Jr, Nicholas L; Reyes, Beverly A S et al. (2014) Morphine-induced trafficking of a mu-opioid receptor interacting protein in rat locus coeruleus neurons. Prog Neuropsychopharmacol Biol Psychiatry 50:53-65
Sun, Jiangwen; Bi, Jinbo; Chan, Grace et al. (2012) Improved methods to identify stable, highly heritable subtypes of opioid use and related behaviors. Addict Behav 37:1138-44
Reyes, B A S; Vakharia, K; Ferraro, T N et al. (2012) Opiate agonist-induced re-distribution of Wntless, a mu-opioid receptor interacting protein, in rat striatal neurons. Exp Neurol 233:205-13
Chan, Grace; Gelernter, Joel; Oslin, David et al. (2011) Empirically derived subtypes of opioid use and related behaviors. Addiction 106:1146-54
Plebani, Jennifer G; Oslin, David W; Lynch, Kevin G (2011) Examining naltrexone and alcohol effects in a minority population: results from an initial human laboratory study. Am J Addict 20:330-6
Guillem, Karine; Peoples, Laura L (2010) Varenicline effects on cocaine self administration and reinstatement behavior. Behav Pharmacol 21:96-103
Guillem, Karine; Peoples, Laura L (2010) Progressive and lasting amplification of accumbal nicotine-seeking neural signals. J Neurosci 30:276-86
Holden, John Michael; Peoples, Laura L (2010) Effects of acute amphetamine exposure on two kinds of Pavlovian approach behavior. Behav Brain Res 208:270-3
Plebani, Jennifer G; Kampman, Kyle M; Lynch, Kevin G (2009) Early abstinence in cocaine pharmacotherapy trials predicts successful treatment outcomes. J Subst Abuse Treat 37:313-7
Fudala, Paul J; Weinrieb, Robert M; Calarco, Joseph S et al. (2003) An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies. Ann Clin Psychiatry 15:121-30

Showing the most recent 10 out of 28 publications